Bishal Gyawali: Revolving door between the regulators and the industry

Bishal Gyawali shared a post on X:

“Revolving door between the regulators and the industry, and why we should be concerned. My new video.”

In this video, Dr. Bishal Gyawali discusses the issue of the “revolving door” between the FDA and the pharmaceutical industry. This term refers to the practice where FDA regulators leave the agency and immediately start working for the pharmaceutical companies they once regulated, often without any cooling-off period.

Dr. Gyawali highlights that the “revolving door” can lead to conflicts of interest, as regulators might be less likely to make decisions that could negatively impact the industry if they are considering future employment there. Such practices can undermine the integrity of the regulatory process and erode public trust.

He concludes by suggesting legislative changes, such as a mandatory cooling-off period of 12 to 24 months before former regulators can join the industry. These changes aim to address conflicts of interest and ensure that regulatory decisions remain unbiased and in the public interest.

Source: Bishal Gyawali/X

Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives.

Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.